Prophylaxis May Cut Cardiotoxicity Risk in HER Breast Cancer

Prophylaxis May Cut Cardiotoxicity Risk in HER+ Breast Cancer

06:00 EST 9 Dec 2018 | MedPageToday

(MedPage Today) -- Clear benefit for anthracycline treatment, not trastuzumab

Original Article: Prophylaxis May Cut Cardiotoxicity Risk in HER+ Breast Cancer

More From BioPortfolio on "Prophylaxis May Cut Cardiotoxicity Risk in HER+ Breast Cancer"